Last updated: February 20, 2026
What Is NDC 00093-1060?
NDC 00093-1060 is marketed as Acyclovir Injection. It is primarily used for treating herpes simplex virus, varicella-zoster virus (shingles), and other related viral infections. It is a prescription medication administered intravenously, typically in hospital or clinical settings.
Market Overview
Market Size and Demand
The global antiviral drug market was valued at approximately USD 20.2 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 7.2% through 2028, driven by increasing incidence of viral infections and expanding antiviral indications (Grand View Research, 2022).
Acyclovir constitutes a significant share within the parenteral antiviral segment. The intravenous formulation primarily targets hospitalized or immunocompromised patients. While oral formulations dominate sales due to outpatient use, IV acyclovir retains importance for severe infections.
Key Market Drivers
- Rising prevalence of herpes virus infections globally.
- Increase in immunocompromised patient populations (HIV/AIDS, transplant recipients).
- Expanding hospital infrastructure and IV medication accessibility.
- Development of new formulations and combination therapies.
Leading Competitors
Major suppliers include:
- GlaxoSmithKline (GSK) – Original manufacturer; historically the largest provider.
- Teva Pharmaceuticals – Generic versions.
- Cipla and Mylan – Other significant generic producers.
Distribution Channels
Hospital pharmacies dominate due to the IV administration route. In outpatient settings, oral formulations are more common, limiting IV acyclovir volume to specialized care.
Price Analysis
Current Pricing
Price points for NDC 00093-1060 vary based on manufacturer, packaging, and geographic region.
| Region |
Average Wholesale Price (AWP) per 50 vials of 10 mg/mL (USD) |
Notes |
| United States |
$220 - $300 |
Exact depends on supplier and volume discounts |
| Europe |
€170 - €240 |
Similar to US pricing, with currency adjustments |
| India (generic market) |
$50 - $80 |
Significantly lower due to local manufacturing |
Price Trends
Between 2015-2021, IV acyclovir prices in the US remained relatively stable until 2020, when supply chain disruptions and increased manufacturing costs led to a ~10% price increase. Generic versions account for nearly 85% of IV acyclovir sales, exerting downward pressure on branded prices.
Future Price Projection
Forecasts suggest stability with potential modest increases aligned with inflation and manufacturing costs:
- 2023: Stable pricing with minor fluctuations (+3% to +5%)
- 2024-2026: Slight upward trend (+2% to +4%) driven by raw material prices and regulatory compliance costs
- Post-2026: Prices may stabilize as market saturation occurs and generics dominate
Regulatory Environment Impact
US FDA
- Approved formulations include 250 mg/10 mL, 500 mg/10 mL, and 10 mg/mL vials.
- Patent considerations: No active patents restrict generic manufacture since patents expired years ago.
- Price controls are limited; reimbursement depends on health plans and hospital negotiations.
Global Policies
- Countries with price control policies (e.g., India) maintain lower prices.
- Patent expiry in most regions has fostered generic competition, increasing access and lowering prices.
Summary
NDC 00093-1060, as IV acyclovir, operates in a competitive environment dominated by generics, with stable yet modest pricing. Market demand remains steady owing to ongoing viral infections, especially among immunocompromised patients.
Key Takeaways
- The global IV acyclovir market is growing modestly, driven by viral disease burden and hospital use.
- Prices in the US range between $220-$300 per 50 vials; in India, prices can be below $80.
- Generics constitute roughly 85% of sales, exerting downward price pressure.
- Future prices will likely increase minimally, following inflation and raw material costs.
- Market expansion may be limited by competition from oral formulations and advances in antiviral therapy.
FAQs
-
What factors influence the pricing of NDC 00093-1060?
Pricing is affected by manufacturing costs, generic competition, supply chain conditions, and regional pricing regulations.
-
How does patent expiry affect market competition?
Patents expiration in most regions has led to a proliferation of generics, reducing prices and increasing market access.
-
Are there any upcoming regulatory changes that could impact prices?
No significant regulatory revisions currently forecasted; however, policies prioritizing drug affordability could influence future prices.
-
What regions show the highest demand for IV acyclovir?
Hospital settings in North America and Europe show the highest demand; emerging markets are growing due to expanding healthcare infrastructure.
-
How does the shift toward oral antivirals impact IV acyclovir?
Oral therapies are preferred for outpatient use; IV acyclovir’s market remains confined to inpatient or severe cases, limiting growth potential.
References
[1] Grand View Research. (2022). Antiviral Drugs Market Size, Share & Trends Analysis Report.
[2] FDA. (2022). Drug Approvals and Regulatory Updates.
[3] IQVIA. (2021). Global Trends in Pharmaceutical Pricing.
[4] Markets and Markets. (2022). Antiviral Drugs Market Forecast.
